Literature DB >> 1378514

Viral DNA carried by human immunodeficiency virus type 1 virions.

F Lori1, F di Marzo Veronese, A L de Vico, P Lusso, M S Reitz, R C Gallo.   

Abstract

A fundamental step in the replication of retroviruses is the reverse transcription of the viral RNA genome into a double-stranded DNA provirus. Retroviruses are believed to carry genomic information only as RNA, and synthesis of DNA is thought to start only after virus entry into the infected cell. We report here that infectious mature human immunodeficiency virus type 1 virions contain viral DNA of heterogeneous size. This heterogeneity seems to result from random stops of reverse transcription during minus- and plus-strand synthesis. The DNA carried by human immunodeficiency virus type 1 virions presumably originates from reverse transcription which takes place prior to or during formation of the mature virus particle.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378514      PMCID: PMC241368     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  HIV: early virus-cell interactions.

Authors:  C Grewe; A Beck; H R Gelderblom
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

2.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

Review 3.  Retroid virus genome replication.

Authors:  W S Mason; J M Taylor; R Hull
Journal:  Adv Virus Res       Date:  1987       Impact factor: 9.937

4.  RNA-dependent DNA polymerase in virions of Rous sarcoma virus.

Authors:  H M Temin; S Mizutani
Journal:  Nature       Date:  1970-06-27       Impact factor: 49.962

5.  Identification and characterization of human immunodeficiency virus type 1 gag-pol fusion protein in transfected mammalian cells.

Authors:  C Peng; N T Chang; T W Chang
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

6.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

Authors:  G M Shaw; B H Hahn; S K Arya; J E Groopman; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

7.  Mouse mammary tumor virus DNA in infected rat cells: characterization of unintegrated forms.

Authors:  G M Ringold; K R Yamamoto; P R Shank; H E Varmus
Journal:  Cell       Date:  1977-01       Impact factor: 41.582

8.  New procedure for the direct analysis of in vitro reverse transcription of Rous sarcoma virus RNA.

Authors:  J L Darlix; P A Bromley; P F Spahr
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

9.  Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals.

Authors:  M C Psallidopoulos; S M Schnittman; L M Thompson; M Baseler; A S Fauci; H C Lane; N P Salzman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  HIV-1 replication is controlled at the level of T cell activation and proviral integration.

Authors:  M Stevenson; T L Stanwick; M P Dempsey; C A Lamonica
Journal:  EMBO J       Date:  1990-05       Impact factor: 11.598

View more
  90 in total

1.  Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication.

Authors:  M Kameoka; L Rong; M Götte; C Liang; R S Russell; M A Wainberg
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells.

Authors:  S Tang; T Murakami; B E Agresta; S Campbell; E O Freed; J G Levin
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

3.  Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1.

Authors:  T Pierson; T L Hoffman; J Blankson; D Finzi; K Chadwick; J B Margolick; C Buck; J D Siliciano; R W Doms; R F Siliciano
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Identification of sequences downstream of the primer binding site that are important for efficient replication of human immunodeficiency virus type 1.

Authors:  X Li; C Liang; Y Quan; R Chandok; M Laughrea; M A Parniak; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 5.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

6.  Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization.

Authors:  Mireille Guyader; Etsuko Kiyokawa; Laurence Abrami; Priscilla Turelli; Didier Trono
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

7.  HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle.

Authors:  R A Fouchier; M Brouwer; N A Kootstra; H G Huisman; H Schuitemaker
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

8.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro.

Authors:  C A Spina; J C Guatelli; D D Richman
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Mutations in human immunodeficiency virus type 1 nucleocapsid protein zinc fingers cause premature reverse transcription.

Authors:  James A Thomas; William J Bosche; Teresa L Shatzer; Donald G Johnson; Robert J Gorelick
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.